-
1
-
-
4544224979
-
Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression
-
Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004; 6: 297-305.
-
(2004)
Cancer Cell
, vol.6
, pp. 297-305
-
-
Luo, J.L.1
Maeda, S.2
Hsu, L.C.3
-
2
-
-
0036151047
-
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
-
ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002; 50: 206-211.
-
(2002)
Gut
, vol.50
, pp. 206-211
-
-
ten Hove, T.1
van Montfrans, C.2
Peppelenbosch, M.P.3
van Deventer, S.J.H.4
-
3
-
-
20444479336
-
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: A randomized, placebocontrolled study
-
Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebocontrolled study. Gastroenterology 2005; 128: 1805-1811.
-
(2005)
Gastroenterology
, vol.128
, pp. 1805-1811
-
-
Jarnerot, G.1
Hertervig, E.2
Friis-Liby, I.3
-
4
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476.
-
(2005)
N Engl J Med
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
-
5
-
-
32044451548
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial
-
quiz 591
-
Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591.
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeerts, P.3
-
6
-
-
34447523749
-
Certolizumab pegol for the treatment of Crohn's disease
-
Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
-
(2007)
N Engl J Med
, vol.357
, pp. 228-238
-
-
Sandborn, W.J.1
Feagan, B.G.2
Stoinov, S.3
-
7
-
-
36749070996
-
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents
-
Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis 2007; 13: 1323-1332.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 1323-1332
-
-
Nesbitt, A.1
Fossati, G.2
Bergin, M.3
-
8
-
-
33646696885
-
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
-
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
-
(2006)
JAMA
, vol.295
, pp. 2275-2285
-
-
Bongartz, T.1
Sutton, A.J.2
Sweeting, M.J.3
-
9
-
-
33746652902
-
Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: Guidelines for clinical approach
-
Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-a therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 1366-1371.
-
(2006)
J Gastroenterol Hepatol
, vol.21
, pp. 1366-1371
-
-
Nathan, D.M.1
Angus, P.W.2
Gibson, P.R.3
-
10
-
-
34547640997
-
Infliximab and the risk of latent viruses reactivation in active Crohn's disease
-
Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007; 13: 896-902.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 896-902
-
-
Lavagna, A.1
Bergallo, M.2
Daperno, M.3
-
11
-
-
25444517037
-
BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment
-
British Thoracic Society Standards of Care Committee
-
British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005; 60: 800-805.
-
(2005)
Thorax
, vol.60
, pp. 800-805
-
-
-
12
-
-
0033581124
-
Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project
-
Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686.
-
(1999)
JAMA
, vol.282
, pp. 677-686
-
-
Dye, C.1
Scheele, S.2
Dolin, P.3
-
13
-
-
42449159053
-
Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe
-
Perez JL, Kupper H, Spencer-Green GT. Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe. Ann Rheum Dis 2005; 64 Suppl 3: 265.
-
(2005)
Ann Rheum Dis
, vol.64
, Issue.SUPPL. 3
, pp. 265
-
-
Perez, J.L.1
Kupper, H.2
Spencer-Green, G.T.3
-
14
-
-
20744440158
-
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
-
Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772.
-
(2005)
Arthritis Rheum
, vol.52
, pp. 1766-1772
-
-
Carmona, L.1
Gomez-Reino, J.J.2
Rodriguez-Valverde, V.3
-
15
-
-
1842479974
-
High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy
-
Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-313.
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, pp. 309-313
-
-
Mow, W.S.1
Abreu-Martin, M.T.2
Papadakis, K.A.3
-
16
-
-
33644643266
-
-
Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54 (RR-15): 49-55.
-
Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54 (RR-15): 49-55.
-
-
-
-
17
-
-
65549123109
-
-
accessed Dec 2007
-
Oxford Immunotec [website]. http://www.oxfordimmunotec.com/ (accessed Dec 2007).
-
Oxford Immunotec [website]
-
-
-
18
-
-
33947523473
-
Meta-analysis: New tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research
-
Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354.
-
(2007)
Ann Intern Med
, vol.146
, pp. 340-354
-
-
Menzies, D.1
Pai, M.2
Comstock, G.3
-
19
-
-
34249888790
-
Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans
-
Rangaka MX, Diwakar L, Seldon R, et al. Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis 2007; 44: 1639-1646.
-
(2007)
Clin Infect Dis
, vol.44
, pp. 1639-1646
-
-
Rangaka, M.X.1
Diwakar, L.2
Seldon, R.3
-
20
-
-
33750949663
-
Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients
-
Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28: 31-34.
-
(2006)
Eur Respir J
, vol.28
, pp. 31-34
-
-
Piana, F.1
Codecasa, L.R.2
Cavallerio, P.3
-
21
-
-
37749054451
-
Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: Performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay
-
Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon γ assay. Ann Rheum Dis 2008: 67: 84-90.
-
(2008)
Ann Rheum Dis
, vol.67
, pp. 84-90
-
-
Matulis, G.1
Jüni, P.2
Villiger, P.M.3
Gadola, S.D.4
-
22
-
-
24144447328
-
Interferon-γ assays for tuberculosis: Is anergy the Achilles' heel?
-
Pai M, Lewinsohn DM. Interferon-γ assays for tuberculosis: is anergy the Achilles' heel? Am J Respir Crit Care Med 2005; 172: 519-521.
-
(2005)
Am J Respir Crit Care Med
, vol.172
, pp. 519-521
-
-
Pai, M.1
Lewinsohn, D.M.2
-
23
-
-
33750485302
-
Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
-
Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-610.
-
(2006)
Nat Clin Pract Rheumatol
, vol.2
, pp. 602-610
-
-
Winthrop, K.L.1
|